<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2022-16-1-97-104</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-6690</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>БРОНХОПУЛЬМОНОЛОГИЯ, ОТОРИНОЛАРИНГОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>BRONCHOPULMONOLOGY, OTORHINOLARYNGOLOGY</subject></subj-group></article-categories><title-group><article-title>Особенности мукоактивной терапии в практике педиатра</article-title><trans-title-group xml:lang="en"><trans-title>Peculiarities of mucoactive therapy in pediatric practice</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6006-7846</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Локшина</surname><given-names>Э. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Lokshina</surname><given-names>E. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p> к.м.н., профессор кафедры педиатрии </p><p> 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1 </p></bio><bio xml:lang="en"><p>Cand. Sci. (Med.), Professor of the Department of Pediatrics </p><p>20, Bldg. 1, Delegateskaya St., Moscow, 127473, Russia</p></bio><email xlink:type="simple">elokshina@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3426-3426</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зайцева</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zaytseva</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д.м.н., профессор, заведующая кафедрой педиатрии </p><p> 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1 </p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor, Head of the Department of Pediatrics</p><p>20, Bldg. 1, Delegateskaya St., Moscow, 127473, Russia</p></bio><email xlink:type="simple">olga6505963@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Московский государственный медико-стоматологический университет имени А.И. Евдокимова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Yevdokimov Moscow State University of Medicine and Dentistry</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>28</day><month>02</month><year>2022</year></pub-date><volume>0</volume><issue>1</issue><fpage>97</fpage><lpage>104</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Локшина Э.Э., Зайцева О.В., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Локшина Э.Э., Зайцева О.В.</copyright-holder><copyright-holder xml:lang="en">Lokshina E.E., Zaytseva O.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/6690">https://www.med-sovet.pro/jour/article/view/6690</self-uri><abstract><p>Кашель является одним из наиболее частых симптомов в ежедневной практике педиатра. Клинически кашель у детей может проявляться от небольшого покашливания, почти не оказывающего влияния на самочувствие и поведение, до сильного, мучительного, нарушающего сон и общее состояние, что значительно ухудшает качество жизни ребенка. Кашель является мультидисциплинарной проблемой из-за большого разнообразия его причин, поэтому в клинической практике педиатра существуют определенные трудности при верификации диагноза, особенно при затяжном кашле, и подборе оптимального лечения. Необходимость в мукоактивной терапии и выбор лекарственного средства прежде всего зависит от причины и характера кашля, особенностей формирования кашлевого рефлекса в детском возрасте, а также механизмов действия применяемых лекарственных средств. Главная задача мукоактивных препаратов – это восстановление мукоцилиарного клиренса и эффективное выведение секрета из дыхательных путей, однако некоторые препараты содержат еще ряд дополнительных свойств. В статье приведены основные причины острого и хронического кашля у детей, рассмотрены современные возможности терапии кашля. Одним из наиболее широко применяемых мукоактивных средств при лечении кашля у детей является амброксол из-за его выраженного муколитического, экспекторирующего, противовоспалительного, антиоксидантного и иммуномодулирующего действия, а также стимуляции  синтеза сурфактанта. Эффективность и благоприятный профиль безопасности амброксола были продемонстрированы в многочисленных международных и российских исследованиях. Широкий выбор лекарственных форм, который обеспечивает разные способы доставки лекарственного вещества, позволяет применять амброксол у детей с острыми и хроническими бронхолегочными заболеваниями с раннего возраста.</p></abstract><trans-abstract xml:lang="en"><p>Cough is one of the most common symptoms in daily pediatric practice. Clinical presentation of cough in children may vary from a slight cough that has almost no impact on well-being and behaviour, to a strong, painful one that disrupts sleep and overall health status, which significantly worsens the child’s quality of life. Cough is a multidisciplinary problem due to a wide variety of causes, that’s why in the clinical pediatric practice there are certain difficulties in verifying the diagnosis, especially in children with prolonged cough, and in selecting the optimal treatment. The need for mucoactive therapy and the choice of a drug primarily depend on the cause and nature of the cough, the features of the development of the cough reflex in childhood, as well as the mechanisms of action of the drugs used. The main purpose of mucoactive drugs is to restore mucociliary clearance and effectively eliminate secretions from the respiratory tract, but apart from them some drugs have a few additional properties. The article presents the main causes of acute and chronic cough in children and considers the modern therapy options to treat cough. Ambroxol is one of the most commonly used mucoactive drugs to treat cough in children due to its pronounced mucolytic, expectorant, anti-inflammatory, antioxidant and immunomodulatory activity, as well as stimulation of surfactant synthesis. Ambroxol has been shown to have efficacy and favourable safety profile in numerous international and Russian studies. A wide choice of dosage forms, which provide different routes of medication administration, allows to use Ambroxol in children with acute and chronic bronchopulmonary diseases from an early age.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>кашель</kwd><kwd>диагностика</kwd><kwd>мукоактивная терапия</kwd><kwd>амброксол</kwd><kwd>дети</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cough</kwd><kwd>diagnosis</kwd><kwd>mucoactive therapy</kwd><kwd>ambroxol</kwd><kwd>children</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Finley C.R., Chan D.S., Garrison S., Korownyk C., Kolber M.R., Campbell S. et al. What are the most common conditions in primary care? Systematic review. Can Fam Phys. 2018;64:832–840. Available at: https://www.cfp.ca/content/64/11/832.</mixed-citation><mixed-citation xml:lang="en">Finley C.R., Chan D.S., Garrison S., Korownyk C., Kolber M.R., Campbell S. et al. What are the most common conditions in primary care? Systematic review. Can Fam Phys. 2018;64:832–840. Available at: https://www.cfp.ca/content/64/11/832.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Morice A.H. Epidemiology of cough. Pulm Pharmacol Ther. 2002;15(3):253–259. https://doi.org/10.1006/pupt.2002.0352.</mixed-citation><mixed-citation xml:lang="en">Morice A.H. Epidemiology of cough. Pulm Pharmacol Ther. 2002;15(3):253–259. https://doi.org/10.1006/pupt.2002.0352.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Marchant J.M., Newcombe P.A., Juniper E.F., Sheffield J.K., Stathis S.L., Chang A.B. What is the burden of chronic cough for families? Chest. 2008;134:303–309. https://doi.org/10.1378/chest.07-2236.</mixed-citation><mixed-citation xml:lang="en">Marchant J.M., Newcombe P.A., Juniper E.F., Sheffield J.K., Stathis S.L., Chang A.B. What is the burden of chronic cough for families? Chest. 2008;134:303–309. https://doi.org/10.1378/chest.07-2236.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hay A.D., Wilson A., Fahey T., Peters T.J. The duration of acute cough in preschool children presenting to primary care: a prospective cohort study. Fam Pract. 2003;20(6):696–705. Available at: https://pubmed.ncbi.nlm.nih.gov/14701895.</mixed-citation><mixed-citation xml:lang="en">Hay A.D., Wilson A., Fahey T., Peters T.J. The duration of acute cough in preschool children presenting to primary care: a prospective cohort study. Fam Pract. 2003;20(6):696–705. Available at: https://pubmed.ncbi.nlm.nih.gov/14701895.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Зайцева О.В. Кашель у детей: рациональный выбор терапии. Медицинский cовет. 2016;(16):68–72. https://doi.org/10.21518/2079-701X-2016-16-68-72.</mixed-citation><mixed-citation xml:lang="en">Zaitseva O.V. Cough in children: rational choice of therapy. Meditsinskiy Sovet. 2016;(16):68–72. (In Russ.) https://doi.org/10.21518/2079-701X-2016-16-68-72.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Самсыгина Г.А. Кашель у детей. Клиническое руководство. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа; 2021. 192 c. Режим доступа: https://library.sammi.uz/Library/Rus%20tilidagi%20adabiyotlar/Педиатрия/Кашель_у_детей_Клиническое_руководство_Самсыгина_Г_А_2021.pdf.</mixed-citation><mixed-citation xml:lang="en">Samsygina G.A. Cough in children: clinical guidelines. 2nd ed., Moscow: GEOTAR-Media; 2021. 192 p. (In Russ.) Available at: https://library.sammi. uz/Library/Rus%20tilidagi%20adabiyotlar/Педиатрия/Кашель_у_детей_Клиническое_руководство_Самсыгина_Г_А_2021.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Таточенко В.К. Дифференциальная диагностика кашля у детей и его лечение. Лечащий врач. 2008;(3):60–65. Режим доступа: https://www.lvrach.ru/2008/03/4910226.</mixed-citation><mixed-citation xml:lang="en">Tatochenko V.K. Differential diagnosis and treatment of cough in children. Lechaschi Vrach. 2008;(3):60–65. (In Russ.) Available at: https://www.lvrach.ru/2008/03/4910226.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Синопальников А.И., Клячкина И.Л. Кашель. Consilium Medicum. 2004;6(10):720–727. Режим доступа: https://consilium.orscience.ru/2075-1753/article/view/91823.</mixed-citation><mixed-citation xml:lang="en">Sinopal’nikov A.I., Klyachkina I.L. Kashel’. Consilium Medicum. 2004;6(10):720–727. (In Russ.) Available at: https://consilium.orscience.ru/2075-1753/article/view/91823.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Чучалин А.Г., Абросимов В.Н. Кашель. 2-е изд., перераб. и доп. М.: Эхо; 2012. 128 с.</mixed-citation><mixed-citation xml:lang="en">Chuchalin A.G., Abrosimov V.N. Cough. 2nd ed., Moscow: Echo; 2012. 128 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Shields M.D., Bush A., Everard M.L., McKenzie S., Primhak R. British Thoracic Society Cough Guideline Group. BTS guidelines: Recommendations for the assessment and management of cough in children. Thorax. 2008;63(3):iii1-iii15. http://doi.org/10.1136/thx.2007.077370.</mixed-citation><mixed-citation xml:lang="en">Shields M.D., Bush A., Everard M.L., McKenzie S., Primhak R. British Thoracic Society Cough Guideline Group. BTS guidelines: Recommendations for the assessment and management of cough in children. Thorax. 2008;63(3):iii1-iii15. http://doi.org/10.1136/thx.2007.077370.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Morice A.H., Millqvist E., Bieksiene K., Birring S.S., Dicpinigaitis P., Domingo Ribas C. et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55(1):1901136. Available at: https://erj.ersjournals.com/content/55/1/1901136.</mixed-citation><mixed-citation xml:lang="en">Morice A.H., Millqvist E., Bieksiene K., Birring S.S., Dicpinigaitis P., Domingo Ribas C. et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55(1):1901136. Available at: https://erj.ersjournals.com/content/55/1/1901136.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Chang A.B. Pediatric cough: children are not miniature adults. Lung. 2010;188(1):33–40. https://doi.org/10.1007/s00408-009-9166-2.</mixed-citation><mixed-citation xml:lang="en">Chang A.B. Pediatric cough: children are not miniature adults. Lung. 2010;188(1):33–40. https://doi.org/10.1007/s00408-009-9166-2.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Chang A.B., Glomb W.B. Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1):260–283. https://doi.org/10.1378/chest.129.1_suppl.260S.</mixed-citation><mixed-citation xml:lang="en">Chang A.B., Glomb W.B. Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1):260–283. https://doi.org/10.1378/chest.129.1_suppl.260S.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Morice A.H., Fontana G.A., Sovijarvi A.R., Pistolesi M., Chung K.F., Widdicombe J. et al. ERS Task Force. The diagnosis and management of chronic cough. Eur Respir J. 2004;24(3):481–492. https://doi.org/10.1183/09031936.04.00027804.</mixed-citation><mixed-citation xml:lang="en">Morice A.H., Fontana G.A., Sovijarvi A.R., Pistolesi M., Chung K.F., Widdicombe J. et al. ERS Task Force. The diagnosis and management of chronic cough. Eur Respir J. 2004;24(3):481–492. https://doi.org/10.1183/09031936.04.00027804.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kantar A., Chang A.B., Shields M.D., Marchant J.M., Grimwood K., Grigg J. et al. ERS statement on protracted bacterial bronchitis in children. Eur Respir J. 2017;50(2):1602139. https://doi.org/10.1183/13993003.02139-2016.</mixed-citation><mixed-citation xml:lang="en">Kantar A., Chang A.B., Shields M.D., Marchant J.M., Grimwood K., Grigg J. et al. ERS statement on protracted bacterial bronchitis in children. Eur Respir J. 2017;50(2):1602139. https://doi.org/10.1183/13993003.02139-2016.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Wurzel D.F., Marchant J.M., Yerkovich S.T., Upham J.W., Petsky H.L., Smith-Vaughan H. et al. Protracted Bacterial Bronchitis in Children: Natural History and Risk Factors for Bronchiectasis. Chest. 2016;150(5):1101–1108. https://doi.org/10.1016/j.chest.2016.06.030.</mixed-citation><mixed-citation xml:lang="en">Wurzel D.F., Marchant J.M., Yerkovich S.T., Upham J.W., Petsky H.L., Smith-Vaughan H. et al. Protracted Bacterial Bronchitis in Children: Natural History and Risk Factors for Bronchiectasis. Chest. 2016;150(5):1101–1108. https://doi.org/10.1016/j.chest.2016.06.030.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Баранов А.А., Козлов Р.С., Намазова-Баранова Л.С., Андреева И.В., Бакрадзе М.Д., Булгакова В.А. и др. Бронхит: клинические рекомендации. М.; 2021. 56 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/381_2.</mixed-citation><mixed-citation xml:lang="en">Baranov A.A., Kozlov R.S., Namazova-Baranova L.S., Andreeva I.V., Bakradze M.D., Bulgakova V.A. et al. Bronchitis: clinical guidelines. Moscow; 2021. 56 p. (In Russ.) Available at: https://cr.minzdrav.gov.ru/recomend/381_2.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Furman E.G., Mazunina E.S., Boytsova E.V., Ovsyannikov D.Y. Protracted bacterial bronchitis in children – the new old disease. Pediatria. 2017;96(2):136–144. (In Russ.) Available at: https://pediatriajournal.ru/files/upload/mags/357/2017_2_4883.pdf.</mixed-citation><mixed-citation xml:lang="en">Furman E.G., Mazunina E.S., Boytsova E.V., Ovsyannikov D.Y. Protracted bacterial bronchitis in children – the new old disease. Pediatria. 2017;96(2):136–144. (In Russ.) Available at: https://pediatriajournal.ru/files/upload/mags/357/2017_2_4883.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Овчинников А.Ю., Солдатский Ю.Л., Митюк А.М. Новый взгляд на лечение кашля у детей. Педиатрическая фармакология. 2013;10(5):18–22. Режим доступа: https://cyberleninka.ru/article/n/novyyvzglyad-na-lechenie-kashlya-u-detey-obzor-literatury/viewer.</mixed-citation><mixed-citation xml:lang="en">Ovchinnikov A.Y., Soldatskiy Y.L., Mityuk A.M. New View on Cough Treatment in Children. Pediatric Pharmacology. 2013;10(5):18–22. (In Russ.) Available at: https://cyberleninka.ru/article/n/novyy-vzglyad-na-lecheniekashlya-u-detey-obzor-literatury/viewer.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Дербенева М.Л., Гусева А.Л. Некоторые аспекты диагностики и лечения кашля. Медицинский совет. 2016;(4):64–67. https://doi.org/10.21518/2079-701X-2016-4-64-67.</mixed-citation><mixed-citation xml:lang="en">Derbeneva M.L., Guseva A.L. Some aspects of diagnosis and treatment of cough. Meditsinskiy Sovet. 2016;(4):64–67. (In Russ.) https://doi.org/10.21518/2079-701X-2016-4-64-67.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Баранов А.А., Лобзин Ю.В., Намазова-Баранова Л.С., Таточенко В.К., Усков А.Н., Куличенко Т.В. и др. Острая респираторная вирусная инфекция (ОРВИ) у детей: клинические рекомендации. М.: МЗ РФ, Союз педиатров России; 2018. 33 с. Режим доступа: https://www.pediatrrussia.ru/information/klin-rek/deystvuyushchie-klinicheskierekomendatsii/%D0%9E%D0%A0%D0%92%D0%98%20%D0%B4%D0%B5%D1%82%D0%B8%20%D0%A1%D0%9F%D0%A0.v1%20+%20T%20+%20K%20_2018.pdf.</mixed-citation><mixed-citation xml:lang="en">Baranov A.A., Lobzin Yu.V., Namazova-Baranova L.S., Tatochenko V.K., Uskov A.N., Kulichenko T.V. et al. Acute respiratory viral infection (ARVI) in children: clinical guidelines. Moscow: Ministry of Health of RF, Union of Pediatricians of Russia; 2018. 33 p. (In Russ.) Available at: https://www.pediatr-russia.ru/information/klin-rek/deystvuyushchie-klinicheskierekomendatsii/%D0%9E%D0%A0%D0%92%D0%98%20%D0%B4%D0%B5%D1%82%D0%B8%20%D0%A1%D0%9F%D0%A0.v1%20+%20T%20+%20K%20_2018.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Зайцев А.А. Мукоактивная фармакотерапия: основы рационального выбора. Практическая пульмонология. 2019;(3):77–82. Режим доступа: https://atmosphere-ph.ru/modules/Magazines/articles//pulmo/pp_3_2019_77.pdf.</mixed-citation><mixed-citation xml:lang="en">Zaitsev A.A. Mucoactive Pharmacotherapy: the Basics of Rational Choice. Prakticheskaya pulʹmonologiya. 2019;(3):77–82. (In Russ.) Available at: https://atmosphere-ph.ru/modules/Magazines/articles//pulmo/pp_3_2019_77.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Новикова Л., Баранова О., Илькович Ю. Применение ацетилцистеина в клинической пульмонологии. Врач. 2014;(2):13–16. Режим доступа: https://elibrary.ru/item.asp?id=21238471.</mixed-citation><mixed-citation xml:lang="en">Novikova L., Baranova O., Ilkovich Yu. Use of acetylcysteine in clinical pulmonology. Vrach. 2014;(2):13–16. (In Russ.) Available at: https://elibrary.ru/item.asp?id=21238471.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Геппе Н.А., Малахов А.Б., Зайцева О.В., Дегтярева М.В., Ильенкова Н.А., Калюжин О.В. и др. Спорные и нерешенные вопросы в терапии кашля у детей в амбулаторной практике. Педиатрия (Прил. к журн. Consilium Medicum). 2017;(4):40–45. Режим доступа: https://cyberleninka.ru/article/n/spornye-i-nereshennye-voprosy-v-terapii-kashlya-u-detey-vambulatornoy-praktike.</mixed-citation><mixed-citation xml:lang="en">Geppe N.A., Malakhov A.B., Zaytseva O.V., Degtyareva M.V., Ilyenkova N.A.,Kalyuzhin O.V. et al. Controversial and unresolved issues in the treatment of cough in children in outpatient practice. Pediatrics. Consilium Medicum. 2017;(4):40–45. (In Russ.) Available at: https://cyberleninka.ru/article/n/spornye-i-nereshennye-voprosy-v-terapii-kashlya-u-detey-vambulatornoy-praktike.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Овсянников Д.Ю., Духанин А.С. Мукоактивная терапия у детей: взгляд педиатра и фармаколога. Вопросы практической педиатрии. 2016;11(4):24–32. https://doi.org/10.20953/1817-7646-2016-4-24-32.</mixed-citation><mixed-citation xml:lang="en">Ovsyannikov D.Yu., Dukhanin A.S. Mucoactive therapy in children: a view of a paediatrician and a pharmacologist. Clinical Practice in Pediatrics. 2016;11(4):24–32. (In Russ.) https://doi.org/10.20953/1817-7646-2016-4-24-32.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Геппе Н.А., Горелов А.В., Козлова Л.В. и др. Острые инфекции дыхательных путей у детей. Диагностика, лечение, профилактика: клиническое руководство. 2-е изд. М.: МедКом-Про; 2020.</mixed-citation><mixed-citation xml:lang="en">Geppe N.A., Gorelov A.V., Kozlova L.V. et al. Acute respiratory infections in children. Diagnosis, treatment, prevention: clinical guidelines. 2nd ed. Moscow: Medcom-pro; 2020. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Зайцева О.В. Рациональный выбор муколитической терапии в лечении болезней органов дыхания у детей. РМЖ. 2009;(19):1217–1222. Режим доступа: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Racionalynyy_vybor_mukoliticheskoy_terapii__v_lechenii_bolezney_organov_dyhaniya_u_detey.</mixed-citation><mixed-citation xml:lang="en">Zaitseva O.V. Rational choice of mucolytic therapy in the treatment of respiratory diseases in children. RMJ. 2009;(19):1217–1222. (In Russ.) Available at: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Racionalynyy_vybor_mukoliticheskoy_terapii__v_lechenii_bolezney_organov_dyhaniya_u_detey.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Захарова И.Н., Дмитриева Ю.А. Дифференцированный подход к терапии кашля у детей. РМЖ. 2013;(24):1153–1160. Режим доступа: https://www.rmj.ru/articles/pediatriya/Differencirovannyy_podhod_k_terapii_kashlya_u_detey.</mixed-citation><mixed-citation xml:lang="en">Zakharova I.N., Dmitrieva Yu.A. Differentiated approach to the therapy of cough in children. RMJ. 2013;(24):1153–1160. (In Russ.) Available at: https://www.rmj.ru/articles/pediatriya/Differencirovannyy_podhod_k_terapii_kashlya_u_detey.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Бабак С.Л., Горбунова М.В., Малявин А.Г. Безопасность амброксола в терапии респираторных заболеваний взрослых. Практическая пульмонология. 2019;(1):84–90. Режим доступа: https://atmosphere-ph.ru/modules/Magazines/articles//pulmo/pp_1_2019_84.pdf.</mixed-citation><mixed-citation xml:lang="en">Babak S.L., Gorbunova M.V., Malyavin A.G. Ambroxol safety for the treatment of respiratory diseases in adults. Prakticheskaya pulʹmonologiya. 2019;(1):84–90. (In Russ.) Available at: https://atmosphere-ph.ru/modules/Magazines/articles//pulmo/pp_1_2019_84.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Wiessmann K.J., Niemeyer K. Clinical results in the treatment of chronic obstructive bronchitis with ambroxol in comparison with bromhexine. Arzneimittelforschung. 1978;28(5a):918–921. Available at: https://pubmed.ncbi.nlm.nih.gov/373777.</mixed-citation><mixed-citation xml:lang="en">Wiessmann K.J., Niemeyer K. Clinical results in the treatment of chronic obstructive bronchitis with ambroxol in comparison with bromhexine. Arzneimittelforschung. 1978;28(5a):918–921. Available at: https://pubmed.ncbi.nlm.nih.gov/373777.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Андреева И.В. Амброксол в лечении и профилактике заболеваний дыхательной системы. Врач. 2008;(5):65–66. Режим доступа: https://elibrary.ru/item.asp?id=12952405.</mixed-citation><mixed-citation xml:lang="en">Andreeva, Yu.V. Ambroxol in the treatment and prevention of respiratory diseases. Vrach. 2008;(5):65–66. (In Russ.) Available at: https://elibrary.ru/item.asp?id=12952405.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Kupczyk M., Kuna P. Mucolytics in acute and chronic respiratory tract disorders. II. Uses for treatment and antioxidant properties. Pol Merkur Lekarski. 2002;12(69):248–252. Available at: https://pubmed.ncbi.nlm.nih.gov/12053601.</mixed-citation><mixed-citation xml:lang="en">Kupczyk M., Kuna P. Mucolytics in acute and chronic respiratory tract disorders. II. Uses for treatment and antioxidant properties. Pol Merkur Lekarski. 2002;12(69):248–252. Available at: https://pubmed.ncbi.nlm.nih.gov/12053601.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang S.J., Jiang J.X., Ren Q.Q., Jia Y.L., Shen J., Shen H.J. et al. Ambroxol inhalation ameliorates LPS-induced airway inflammation and mucus secretion through the extracellular signal-regulated kinase 1/2 signaling pathway. Eur J Pharmacol. 2016;775:138–148. https://doi.org/10.1016/j.ejphar.2016.02.030.</mixed-citation><mixed-citation xml:lang="en">Zhang S.J., Jiang J.X., Ren Q.Q., Jia Y.L., Shen J., Shen H.J. et al. Ambroxol inhalation ameliorates LPS-induced airway inflammation and mucus secretion through the extracellular signal-regulated kinase 1/2 signaling pathway. Eur J Pharmacol. 2016;775:138–148. https://doi.org/10.1016/j.ejphar.2016.02.030.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Stetinova V., Herout V., Kvetina J. In vitro and in vivo antioxidant activity of ambroxol. Clin Exp Med. 2004;4(3):152–158. https://doi.org/10.1007/s10238-004-0050-3.</mixed-citation><mixed-citation xml:lang="en">Stetinova V., Herout V., Kvetina J. In vitro and in vivo antioxidant activity of ambroxol. Clin Exp Med. 2004;4(3):152–158. https://doi.org/10.1007/s10238-004-0050-3.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Beeh K.M., Beier J., Esperester A., Paul L.D. Antiinflammatory properties of ambroxol. Eur J Med Res. 2008;(13):557–562. Available at: https://pubmed.ncbi.nlm.nih.gov/19073395.</mixed-citation><mixed-citation xml:lang="en">Beeh K.M., Beier J., Esperester A., Paul L.D. Antiinflammatory properties of ambroxol. Eur J Med Res. 2008;(13):557–562. Available at: https://pubmed.ncbi.nlm.nih.gov/19073395.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Gaida W., Klinder K., Arndt K., Weiser T. Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. Neuropharmacology. 2005;49(8):1220–1227. https://doi.org/10.1016/j.neuropharm.2005.08.004.</mixed-citation><mixed-citation xml:lang="en">Gaida W., Klinder K., Arndt K., Weiser T. Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. Neuropharmacology. 2005;49(8):1220–1227. https://doi.org/10.1016/j.neuropharm.2005.08.004.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Leffler A., Reckzeh J., Nau C. Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites. Eur J Pharmacol. 2010;630(1–3):19–28. https://doi.org/10.1016/j.ejphar.2009.12.027.</mixed-citation><mixed-citation xml:lang="en">Leffler A., Reckzeh J., Nau C. Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites. Eur J Pharmacol. 2010;630(1–3):19–28. https://doi.org/10.1016/j.ejphar.2009.12.027.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Gibbs B.F., Schmutzler W., Vollrath I.B., Brosthardt P., Braam U., Wolff H.H. et al. Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Inflamm Res. 1999;48(2):86–93. https://doi.org/10.1007/s000110050421.</mixed-citation><mixed-citation xml:lang="en">Gibbs B.F., Schmutzler W., Vollrath I.B., Brosthardt P., Braam U., Wolff H.H. et al. Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Inflamm Res. 1999;48(2):86–93. https://doi.org/10.1007/s000110050421.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Yang B., Yao D.F., Ohuchi M., Ide M., Yano M., Okumura Y. et al. Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur Respir J. 2002;19(5):952–958. https://doi.org/10.1183/09031936.02.00253302.</mixed-citation><mixed-citation xml:lang="en">Yang B., Yao D.F., Ohuchi M., Ide M., Yano M., Okumura Y. et al. Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur Respir J. 2002;19(5):952–958. https://doi.org/10.1183/09031936.02.00253302.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Kido H., Okumura Y., Yamada H., Mizuno D., Higashi Y., Yano M. Secretory leukoprotease inhibitor and pulmonary surfactant serve as principal defenses against influenza a virus infection in the airway and chemical agents up-regulating their levels may have therapeutic potential. Biol Chem. 2004;385(11):1029–1034. https://doi.org/10.1515/BC.2004.133.</mixed-citation><mixed-citation xml:lang="en">Kido H., Okumura Y., Yamada H., Mizuno D., Higashi Y., Yano M. Secretory leukoprotease inhibitor and pulmonary surfactant serve as principal defenses against influenza a virus infection in the airway and chemical agents up-regulating their levels may have therapeutic potential. Biol Chem. 2004;385(11):1029–1034. https://doi.org/10.1515/BC.2004.133.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Cataldi M., Sblendorio V., Leo A., Piazza O. Biofilm-dependent airway infections: a role for ambroxol? Pulm Pharmacol Ther. 2014;28(2):98–108. https://doi.org/10.1016/j.pupt.2013.11.002.</mixed-citation><mixed-citation xml:lang="en">Cataldi M., Sblendorio V., Leo A., Piazza O. Biofilm-dependent airway infections: a role for ambroxol? Pulm Pharmacol Ther. 2014;28(2):98–108. https://doi.org/10.1016/j.pupt.2013.11.002.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Yamaya M., Nishimura H., Nadine L.K., Ota C., Kubo H., Nagatomi R. Ambroxol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Arch Pharm Res. 2014;37(4):520–529. https://doi.org/10.1007/s12272-013-0210-7.</mixed-citation><mixed-citation xml:lang="en">Yamaya M., Nishimura H., Nadine L.K., Ota C., Kubo H., Nagatomi R. Ambroxol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Arch Pharm Res. 2014;37(4):520–529. https://doi.org/10.1007/s12272-013-0210-7.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Fan Y.Z., Wen Z.L. Efficacy of different dosages of ambroxol hydrochloride in the prevention of neonatal respiratory distress syndrome. Zhongguo Dang Dai Er Ke Za Zhi. 2009;11(9):771–772. Available at: https://pubmed.ncbi.nlm.nih.gov/19755033.</mixed-citation><mixed-citation xml:lang="en">Fan Y.Z., Wen Z.L. Efficacy of different dosages of ambroxol hydrochloride in the prevention of neonatal respiratory distress syndrome. Zhongguo Dang Dai Er Ke Za Zhi. 2009;11(9):771–772. Available at: https://pubmed.ncbi.nlm.nih.gov/19755033.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Baldini G., Gucci M., Tarò D., Memmini C. a controlled study on the action of a new formulation of ambroxol in asthmatiform bronchitis in children. Minerva Pediatr. 1989;41(2):91–95. Available at: https://pubmed.ncbi.nlm.nih.gov/2661989.</mixed-citation><mixed-citation xml:lang="en">Baldini G., Gucci M., Tarò D., Memmini C. a controlled study on the action of a new formulation of ambroxol in asthmatiform bronchitis in children. Minerva Pediatr. 1989;41(2):91–95. Available at: https://pubmed.ncbi.nlm.nih.gov/2661989.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Malerba M., Ponticiello A., Radaeli A., Bensi G., Grassi V. Effect of twelvemonths therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebocontrolled study (the AMETHIST Trial). Pulm Pharmacol Ther. 2004;17(1):27–34. https://doi.org/10.1016/j.pupt.2003.08.004.</mixed-citation><mixed-citation xml:lang="en">Malerba M., Ponticiello A., Radaeli A., Bensi G., Grassi V. Effect of twelvemonths therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebocontrolled study (the AMETHIST Trial). Pulm Pharmacol Ther. 2004;17(1):27–34. https://doi.org/10.1016/j.pupt.2003.08.004.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Malerba M., Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol. 2008;4(8):1119–1129. https://doi.org/10.1517/17425255.4.8.1119.</mixed-citation><mixed-citation xml:lang="en">Malerba M., Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol. 2008;4(8):1119–1129. https://doi.org/10.1517/17425255.4.8.1119.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Княжеская Н.П., Бобков Е.В. Современная муколитическая терапия заболеваний дыхательных путей. РМЖ. 2018;3(I):30–35. Режим доступа: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Sovremennaya_mukoliticheskaya_terapiya_zabolevaniy_dyhatelynyh_putey.</mixed-citation><mixed-citation xml:lang="en">Kniazheskaya N.P., Bobkov E.V. Curent mucolytic therapy of respiratory tract diseases. RMJ. 2018;3(I):30–35. (In Russ.) Available at: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Sovremennaya_mukoliticheskaya_terapiya_zabolevaniy_dyhatelynyh_putey.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Клячкина И.Л., Синопальников А.И. Амброксол в программе лечения хронических бронхолегочных заболеваний. Практическая пульмонология. 2018;(2):83–92. Режим доступа: https://atmosphere-ph.ru/modules/Magazines/articles//pulmo/pp_2_2018_83.pdf.</mixed-citation><mixed-citation xml:lang="en">Klyachkina I.L., Sinopalnikov A.I. Roxol for the treatment of chronic bronchopulmonary diseases. Prakticheskaya pulʹmonologiya. 2018;(2):83–92. (In Russ.) Available at: https://atmosphere-ph.ru/modules/Magazines/articles//pulmo/pp_2_2018_83.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Fashner J., Ericson K., Werner S. Treatment of the common cold in children and adults. American Family Physician. 2012;86(2):153–159. Available at: https://pubmed.ncbi.nlm.nih.gov/22962927.</mixed-citation><mixed-citation xml:lang="en">Fashner J., Ericson K., Werner S. Treatment of the common cold in children and adults. American Family Physician. 2012;86(2):153–159. Available at: https://pubmed.ncbi.nlm.nih.gov/22962927.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Wunderer H., Morgenroth K., Weis G. The cleaning system of the airways: physiology, pathophysiology and effects of ambroxol. Med Monatsschr Pharm. 2009;32(2):42–47. Available at: https://pubmed.ncbi.nlm.nih.gov/19263911.</mixed-citation><mixed-citation xml:lang="en">Wunderer H., Morgenroth K., Weis G. The cleaning system of the airways: physiology, pathophysiology and effects of ambroxol. Med Monatsschr Pharm. 2009;32(2):42–47. Available at: https://pubmed.ncbi.nlm.nih.gov/19263911.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">de Mey C., Peil H., Kölsch S., Bubeck J., Vix J.M. Efficacy and safety of ambroxol lozenges in the treatment of acute uncomplicated sore throat. EBM-based clinical documentation. Arzneimittelforschung. 2008;58(11):557–568. https://doi.org/10.1055/s-0031-1296557.</mixed-citation><mixed-citation xml:lang="en">de Mey C., Peil H., Kölsch S., Bubeck J., Vix J.M. Efficacy and safety of ambroxol lozenges in the treatment of acute uncomplicated sore throat. EBM-based clinical documentation. Arzneimittelforschung. 2008;58(11):557–568. https://doi.org/10.1055/s-0031-1296557.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Chenot J.F., Weber P., Friede T. Efficacy of Ambroxol lozenges for pharyngitis: a meta-analysis. BMC Fam Pract. 2014;15:45. https://doi.org/10.1186/1471-2296-15-45.</mixed-citation><mixed-citation xml:lang="en">Chenot J.F., Weber P., Friede T. Efficacy of Ambroxol lozenges for pharyngitis: a meta-analysis. BMC Fam Pract. 2014;15:45. https://doi.org/10.1186/1471-2296-15-45.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Poole P., Chong J., Cates C.J. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;(7):CD001287. https://doi.org/10.1002/14651858.CD001287.pub5.</mixed-citation><mixed-citation xml:lang="en">Poole P., Chong J., Cates C.J. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;(7):CD001287. https://doi.org/10.1002/14651858.CD001287.pub5.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Кашель как междисциплинарная проблема в практике врача первичного звена. Эффективная фармакотерапия. 2018;(10):98–105. Режим доступа: https://umedp.ru/upload/iblock/b38/effektivnaya_farmakoterapiya_2018_pulmonologiya_i_otorinolaringologiya_1.pdf.</mixed-citation><mixed-citation xml:lang="en">Cough as the Cross-Cutting Issue in the Practice of the Primary Care Physician. Effective Pharmacotherapy. 2018;(10):98–105. (In Russ.) Available at: https://umedp.ru/upload/iblock/b38/effektivnaya_farmakoterapiya_2018_pulmonologiya_i_otorinolaringologiya_1.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Olivieri D., Zavattini G., Tomasini G., Daniotti S., Bonsignore G., Ferrara G. et al. Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo. Respiration. 1987;51(1):42–51. https://doi.org/10.1159/000195274.</mixed-citation><mixed-citation xml:lang="en">Olivieri D., Zavattini G., Tomasini G., Daniotti S., Bonsignore G., Ferrara G. et al. Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo. Respiration. 1987;51(1):42–51. https://doi.org/10.1159/000195274.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang H., Liu J., Liu T., Wang Y., Dai W. Antenatal maternal medication administration in preventing respiratory distress syndrome of premature infants: a network meta-analysis. Clin Respir J. 2018;12(10):2480–2490. https://doi.org/10.1111/crj.12923.</mixed-citation><mixed-citation xml:lang="en">Zhang H., Liu J., Liu T., Wang Y., Dai W. Antenatal maternal medication administration in preventing respiratory distress syndrome of premature infants: a network meta-analysis. Clin Respir J. 2018;12(10):2480–2490. https://doi.org/10.1111/crj.12923.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Disse B.G. The pharmacology of ambroxol-review and new results. Eur J Respir Dis Suppl. 1987;153:255–262. Available at: https://pubmed.ncbi.nlm.nih.gov/3322865.</mixed-citation><mixed-citation xml:lang="en">Disse B.G. The pharmacology of ambroxol-review and new results. Eur J Respir Dis Suppl. 1987;153:255–262. Available at: https://pubmed.ncbi.nlm.nih.gov/3322865.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Principi N., Zavattini G., Daniotti S. Possibility of interaction among antibiotics and mucolytics in children. Int J Clin Pharmacol Res. 1986;6(5):369–372. Available at: https://pubmed.ncbi.nlm.nih.gov/3781700.</mixed-citation><mixed-citation xml:lang="en">Principi N., Zavattini G., Daniotti S. Possibility of interaction among antibiotics and mucolytics in children. Int J Clin Pharmacol Res. 1986;6(5):369–372. Available at: https://pubmed.ncbi.nlm.nih.gov/3781700.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Paleari D., Rossi G.A., Nicolini G., Olivieri D. Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood. Expert Opin Drug Discov. 2011;6(11):1203–1214. https://doi.org/10.1517/17460441.2011.629646.</mixed-citation><mixed-citation xml:lang="en">Paleari D., Rossi G.A., Nicolini G., Olivieri D. Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood. Expert Opin Drug Discov. 2011;6(11):1203–1214. https://doi.org/10.1517/17460441.2011.629646.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Ratjen F., Wönne R., Posselt H.G., Stöver B., Hofmann D., Bender S.W. a double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur J Pediatr. 1985;144(4):374–378. https://doi.org/10.1007/BF00441781.</mixed-citation><mixed-citation xml:lang="en">Ratjen F., Wönne R., Posselt H.G., Stöver B., Hofmann D., Bender S.W. a double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur J Pediatr. 1985;144(4):374–378. https://doi.org/10.1007/BF00441781.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Passàli D., Zavattini G. Multicenter study on the treatment of secretory otitis media with ambroxol. Importance of a surface-tension-lowering substance. Respiration. 1987;51(1):52–59. https://doi.org/10.1159/000195275.</mixed-citation><mixed-citation xml:lang="en">Passàli D., Zavattini G. Multicenter study on the treatment of secretory otitis media with ambroxol. Importance of a surface-tension-lowering substance. Respiration. 1987;51(1):52–59. https://doi.org/10.1159/000195275.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Golusiński W., Szmeja Z., Szyfter W., Kruk-Zagajewska A., Mielcarek-Kuchta D., Laczkowska-Przybylska J. The use of mucolytic preparations (Mucosolvan) in nasal and paranasal sinuses in children. Otolaryngol Pol. 1996;50(6): 599–606. Available at: https://pubmed.ncbi.nlm.nih.gov/9173390.</mixed-citation><mixed-citation xml:lang="en">Golusiński W., Szmeja Z., Szyfter W., Kruk-Zagajewska A., Mielcarek-Kuchta D., Laczkowska-Przybylska J. The use of mucolytic preparations (Mucosolvan) in nasal and paranasal sinuses in children. Otolaryngol Pol. 1996;50(6): 599–606. Available at: https://pubmed.ncbi.nlm.nih.gov/9173390.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Зайцева О.В., Чечкова О.Б., Пронина С.В., Егоров Л.М., Лихарева Л.В., Клендар Г.А. и др. Результаты изучения эффективности Амбробене в комплексном лечении болезней органов дыхания у детей. Педиатрия. Журнал имени Г.Н. Сперанского. 2003;82(1):80–85. Режим доступа: https://pediatriajournal.ru/files/upload/mags/312/2003_1_2988.pdf.</mixed-citation><mixed-citation xml:lang="en">Zaitseva O.V., Chechkova O.B., Pronina S.V., Egorov L.M., Lihareva L.V., Klendar G.A. et al. Results of studying the effectiveness of Ambrobene in the complex treatment of respiratory diseases in children. Pediatria. 2003;82(1):80–85. (In Russ.) Available at: https://pediatriajournal.ru/files/upload/mags/312/2003_1_2988.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Геппе Н.А., Батырева О.В., Малышев В.С., Утюшева М.Г., Старостина Л.С. Волнообразное течение бронхиальной астмы. Терапия обострений. Трудный пациент. 2007;2(5):43–46. Режим доступа: https://t-pacient.ru/archive/7441</mixed-citation><mixed-citation xml:lang="en">Geppe N.A., Batyreva O.V., Malyshev V.S., Utyusheva M.G., Starostina L.S. Intermittent course of bronchial asthma. Treatment of exacerbations. Difficult Patient. 2007;2(5):43–46. (In Russ.) Available at: https://t-pacient.ru/archive/7441.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Рашитова Э.Л., Закирова А.М., Кадриев А.Г., Кадриев А.А. Муколитики в терапии респираторных заболеваний в педиатрической практике. Медицинский совет. 2020;(10):48–54. https://doi.org/10.21518/2079-701X-2020-10-48-54.</mixed-citation><mixed-citation xml:lang="en">Rashitova E.L., Zakirova A.M., Kadriev A.G., Kadriev A.A. Mukolitics in the therapy of respiratory diseases in pediatric practice. Meditsinskiy Sovet. 2020;(10):48–54. (In Russ.) https://doi.org/10.21518/2079-701X-2020-10-48-54.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Kantar A., Klimek L., Cazan D., Sperl A., Sent U., Mesquita M. An overview of efficacy and safety of ambroxol for the treatment of acute and chronic respiratory diseases with a special regard to children. Multidiscip Respir Med. 2020;15(1):511. https://doi.org/10.4081/mrm.2020.511.</mixed-citation><mixed-citation xml:lang="en">Kantar A., Klimek L., Cazan D., Sperl A., Sent U., Mesquita M. An overview of efficacy and safety of ambroxol for the treatment of acute and chronic respiratory diseases with a special regard to children. Multidiscip Respir Med. 2020;15(1):511. https://doi.org/10.4081/mrm.2020.511.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Симонова О.И. Клинические эффекты амброксола гидрохлорида (Лазолвана®): от чего зависит эффективность препарата? Педиатрия. Журнал имени Г.Н. Сперанского. 2011;90(5):128–133. Режим доступа: https://cyberleninka.ru/article/n/klinicheskie-effekty-ambroksolagidrohlorida-lazolvana-ot-chego-zavisit-effektivnost-preparata.</mixed-citation><mixed-citation xml:lang="en">Simonova O.I. Clinical effects of ambroxol hydrochloride (Lazolvan®): what determines the effectiveness of the drug? Pediatria. 2011;90(5):128–133. (In Russ.) Available at: https://cyberleninka.ru/article/n/klinicheskie-effekty-ambroksola-gidrohlorida-lazolvana-ot-chegozavisit-effektivnost-preparata.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
